Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.32 |
| ▸ | ALB | P02768 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8743030 | 1.00 | FGFR1 (0.36) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL8743037 | 1.00 | FGFR1 (0.36) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| Hydrochloric Acid SCHEMBL22411438 | 0.99 | FGFR1 (0.36) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| Hydrochloric Acid SCHEMBL31390165 | 0.99 | FGFR1 (0.36) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL9119777 | 0.82 | — | — | |
| SCHEMBL8926331 | 0.80 | FGFR1 (0.36) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL9177313 | 0.80 | FGFR1 (0.36) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL8742913 | 0.79 | ALB (0.35) | ALB | |
| SCHEMBL8743024 | 0.79 | ALB (0.35) | ALB | |
| SCHEMBL8743028 | 0.79 | ALB (0.35) | ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5464826-A | Antitumor, anticarcinogenic agents, treatment of herpes | ELI LILLY AND COMPANY (US) | 1995-11-07 | — | — | US | claimed |
| EP-0184365-B1 | IMPROVEMENTS IN THE TREATMENT OF TUMORS IN MAMMALS | ELI LILLY AND COMPANY (US) | 1993-08-04 | — | — | EP | claimed |
| EP-0122707-B1 | IMPROVEMENTS IN OR RELATING TO NOVEL DIFLUORO ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1987-09-16 | — | — | EP | claimed |
| EP-0184365-A2 | Improvements in the treatment of tumors in mammals | ELI LILLY AND COMPANY (US) | 1986-06-11 | — | — | EP | claimed |
| EP-0122707-A1 | Improvements in or relating to novel difluoro antiviral agents | ELI LILLY AND COMPANY (US) | 1984-10-24 | — | — | EP | claimed |
| US-20250064784-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHODS OF TREATMENT | SHAARE ZEDEK SCIENTIFIC LTD. (IL) | 2025-02-27 | — | — | US | disclosed |
| US-12171746-B2 | Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture | LIPOMEDIX PHARMACEUTICALS LTD. (IL) | 2024-12-24 | — | — | US | disclosed |
| US-20220087975-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHOD OF MANUFACTURE | SHAARE ZEDEK SCIENTIFIC LTD. (IL) | 2022-03-24 | — | — | US | disclosed |
| EP-3908261-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHOD OF MANUFACTURE | Lipomedix Pharmaceuticals Ltd. (IL) | 2021-11-17 | — | — | EP | disclosed |
| CN-113453668-A | Liposome composition containing liposome prodrug of mitomycin C and preparation method thereof | 利普麦迪克斯制药有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3151864-B1 | COMBINATION THERAPY COMPRISING A LIPOSOMAL PRODRUG OF MITOMYCIN C AND RADIOTHERAPY | LIPOMEDIX PHARMACEUTICALS LTD (IL) | 2020-08-05 | — | — | EP | disclosed |
| WO-2020144657-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHOD OF MANUFACTURE | LIPOMEDIX PHARMACEUTICALS LTD. (IL) | 2020-07-16 | — | — | WO | disclosed |
| EP-0368668-A2 | Antibody-drug conjugates | ELI LILLY AND COMPANY (US) | 1990-05-16 | — | — | EP | disclosed |
| US-4808614-A | Difluoro antivirals and intermediate therefor | ELI LILLY AND COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0122707-B1 | IMPROVEMENTS IN OR RELATING TO NOVEL DIFLUORO ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4692434-A | NUCLEOSIDES | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| EP-0184365-A2 | Improvements in the treatment of tumors in mammals | ELI LILLY AND COMPANY (US) | 1986-06-11 | — | — | EP | disclosed |
| US-4526988-A | Hydrolyzing alkyl 3-dioxolanyl-2,2-difluoro-3-hydroxy propionate | ELI LILLY AND COMPANY (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0122707-A1 | Improvements in or relating to novel difluoro antiviral agents | ELI LILLY AND COMPANY (US) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087975-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHOD OF MANUFACTURE | LIPC, MLEC, LPXN | FGFR1 4672/4885SLC22A6 2931/4885PDE3A 302/4885 |
| US-12171746-B2 | Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture | LIPC, MLEC, LPXN | FGFR1 4672/4885SLC22A6 2931/4885PDE3A 302/4885 |
| US-20250064784-A1 | LIPOSOME COMPOSITION COMPRISING LIPOSOMAL PRODRUG OF MITOMYCIN C AND METHODS OF TREATMENT | MLEC, LIPC, LPXN | FGFR1 4686/4885SLC22A6 2677/4885PDE3A 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.